Skip to main content Skip to section navigation Skip to footer
Top
Lantern Pharma Inc.
INVESTORS
Home
Investors
Contact
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
ContactInvestors

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Media Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Media Coverage
  • Email Alerts
Jan 05, 2023 8:59am EST

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

Dec 15, 2022 8:00am EST

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting

Dec 13, 2022 8:00am EST

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

Dec 02, 2022 8:00am EST

Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET

Nov 22, 2022 8:00am EST

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting

Nov 07, 2022 4:01pm EST

Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights

Nov 02, 2022 8:00am EDT

Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4

Oct 31, 2022 8:00am EDT

Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET

Oct 25, 2022 8:00am EDT

Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences

Oct 21, 2022 7:00am EDT

Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 18
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

Join our Mailing List to get the latest Lantern news, sent right to your inbox

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.
Never spam. Unsubscribe anytime.
Tweets by LanternPharma
View on Webflow
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board Of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
Investors
Contact
TwitterYoutubeLinkedin
©Copyright 2025 Lantern Pharma Inc.
Privacy Policy